JP4520033B2 - 薬草抽出物の化学的および薬理学的標準化 - Google Patents

薬草抽出物の化学的および薬理学的標準化 Download PDF

Info

Publication number
JP4520033B2
JP4520033B2 JP2000507241A JP2000507241A JP4520033B2 JP 4520033 B2 JP4520033 B2 JP 4520033B2 JP 2000507241 A JP2000507241 A JP 2000507241A JP 2000507241 A JP2000507241 A JP 2000507241A JP 4520033 B2 JP4520033 B2 JP 4520033B2
Authority
JP
Japan
Prior art keywords
cvt
extract
chemical
pharmacological
herbal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000507241A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001513533A (ja
JP2001513533A5 (enExample
Inventor
ケー ティー パン，ピーター
ジェイ シャン，ジャクリーヌ
ワイ チュウ，カム
Original Assignee
エフエックス ライフ サイエンシズ アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフエックス ライフ サイエンシズ アクチェンゲゼルシャフト filed Critical エフエックス ライフ サイエンシズ アクチェンゲゼルシャフト
Publication of JP2001513533A publication Critical patent/JP2001513533A/ja
Publication of JP2001513533A5 publication Critical patent/JP2001513533A5/ja
Application granted granted Critical
Publication of JP4520033B2 publication Critical patent/JP4520033B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
JP2000507241A 1997-08-28 1998-08-28 薬草抽出物の化学的および薬理学的標準化 Expired - Fee Related JP4520033B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5609297P 1997-08-28 1997-08-28
US60/056,092 1997-08-28
PCT/US1998/017344 WO1999009837A1 (en) 1997-08-28 1998-08-28 Chemical and pharmacological standardization of herbal extracts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009218142A Division JP5491114B2 (ja) 1997-08-28 2009-09-18 薬草抽出物の化学的および薬理学的標準化

Publications (3)

Publication Number Publication Date
JP2001513533A JP2001513533A (ja) 2001-09-04
JP2001513533A5 JP2001513533A5 (enExample) 2008-07-03
JP4520033B2 true JP4520033B2 (ja) 2010-08-04

Family

ID=22002097

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000507241A Expired - Fee Related JP4520033B2 (ja) 1997-08-28 1998-08-28 薬草抽出物の化学的および薬理学的標準化
JP2009218142A Expired - Lifetime JP5491114B2 (ja) 1997-08-28 2009-09-18 薬草抽出物の化学的および薬理学的標準化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009218142A Expired - Lifetime JP5491114B2 (ja) 1997-08-28 2009-09-18 薬草抽出物の化学的および薬理学的標準化

Country Status (8)

Country Link
US (1) US6156291A (enExample)
EP (1) EP1006802A4 (enExample)
JP (2) JP4520033B2 (enExample)
KR (1) KR20010023208A (enExample)
CN (1) CN1268027A (enExample)
AU (1) AU9029298A (enExample)
CA (1) CA2301860C (enExample)
WO (1) WO1999009837A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432454B1 (en) * 1997-12-12 2002-08-13 C. V. Technologies, Inc. Processes of making north american ginseng fractions, products containing them, and use as immunomodulators
DK1066042T3 (da) * 1998-03-26 2006-12-18 Phytopharm Plc Steroidale saponiner til behandling af Alzheimers sygdom
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
JP2001139483A (ja) * 1999-08-30 2001-05-22 Japan Science & Technology Corp 薬用人蔘からなる脳細胞または神経細胞保護剤
KR20020035855A (ko) 1999-08-30 2002-05-15 마쯔오 미쯔요시 약용인삼을 포함하는 뇌세포 또는 신경세포 보호제
CA2307393A1 (en) 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
US6771369B2 (en) * 2002-03-12 2004-08-03 Analytical Spectral Devices, Inc. System and method for pharmacy validation and inspection
US6884627B2 (en) * 2002-04-05 2005-04-26 Advanced Gene Technology, Corp. Method for ascertaining the quality of herbs
US6855343B2 (en) * 2002-05-21 2005-02-15 Advanced Gene Technology, Corp Method to ascertain the quality of herbs
WO2004040259A2 (en) * 2002-10-25 2004-05-13 Sloan-Kettering Institute For Cancer Research Screening, quantitation and identification of active ingredients in natural products
US7491753B2 (en) 2003-07-03 2009-02-17 Mallard Creek Polymers, Inc. Antimicrobial and antistatic polymers and methods of using such polymers on various substrates
KR20070057779A (ko) * 2004-07-16 2007-06-07 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 베타-아밀로이드 펩티드 생산을 저해함으로써알츠하이머병을 치료하는 화합물 및 이들의 제조
TWI285262B (en) * 2005-06-20 2007-08-11 Dev Center Biotechnology Characteristic mass spectrum fingerprinting setting method and rapid identification method of Chinese herb medicine and prescription
US20070048249A1 (en) 2005-08-24 2007-03-01 Purdue Research Foundation Hydrophilized bactericidal polymers
RU2444541C2 (ru) 2006-08-24 2012-03-10 Маллард Крик Полимерс, Инк. Катионный латекс в качестве носителя биоактивных ингредиентов и способы его получения и использования
KR101459805B1 (ko) * 2007-03-30 2014-11-07 9898 리미티드 천연 산물 개발을 위한 약제 플랫폼 기법
MY160074A (en) 2008-01-24 2017-02-15 Raptor Therapeutics Inc Protopanaxadiol-type ginsenoside compositions and uses thereof
JP5879037B2 (ja) 2008-02-29 2016-03-08 バレアント カナダ エルピー 人参抽出物による先天免疫応答および適応免疫応答の活性化
US20100278944A1 (en) * 2009-05-04 2010-11-04 Naturex, S.A. Application of american ginseng to enhance neurocognitive function
US9956241B2 (en) 2009-05-04 2018-05-01 Naturex, S.A. Application of American Ginseng to enhance neurocognitive function
KR20110007473A (ko) * 2009-07-16 2011-01-24 씨제이제일제당 (주) 진세노사이드 강화 분획물을 포함하는 혈압 강하용 조성물
JP5563285B2 (ja) * 2009-12-14 2014-07-30 ライオン株式会社 飲食品、医薬品、又は医薬部外品、並びに、プロトパナキサトリオールの安定化方法、及びプロトパナキサジオールの安定化方法
US20110177179A1 (en) * 2010-01-18 2011-07-21 Sinoveda Canada, Inc. Preparation of botanical extracts containing absorbable components using pharmaceutical platform technology
JP2016512502A (ja) * 2013-03-14 2016-04-28 ゾンチャオ ジャン 生薬の活性成分を判断するための方法、それらの生成源、およびそれらの生成のための触媒経路
US20150044306A1 (en) 2013-08-12 2015-02-12 Melvin Mitchell Process for fractionation and extraction of herbal plant material to isolate extractives for pharmaceuticals and nutraceuticals
US20160085941A1 (en) * 2015-03-13 2016-03-24 Jianyi Zhang Method of Discovery of Effective Components in Herbals Based on Evidences by Reversed-directed Analysis
WO2018222622A1 (en) 2017-05-27 2018-12-06 Poly Group LLC Dispersible antimicrobial complex and coatings therefrom
EP3638740B1 (en) 2017-06-16 2024-08-07 Poly Group LLC Polymeric antimicrobial surfactant
BE1027552B1 (fr) 2019-09-03 2021-03-30 Botalys Sa Composition du ginseng et son utilisation comme medicament pour le traitement ou la prevention du stress
WO2021043389A1 (en) 2019-09-03 2021-03-11 Botalys Sa Ginseng composition and use thereof as a medicament for treatment or prevention of an impaired cognition
WO2021043927A1 (en) 2019-09-03 2021-03-11 Botalys Sa Ginseng composition and use thereof as a medicament
BE1027772B1 (fr) 2019-11-21 2021-06-21 Botalys Sa Composition de ginseng pour ameliorer l'etat de la peau et son utilisation pour le traitement d'une maladie dermatologique
US10881983B2 (en) * 2019-09-18 2021-01-05 The Winning Combination Method for extraction of ethyl maltol from passion flower

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753397A (ja) * 1993-08-19 1995-02-28 Inahata Koryo Kk 変異原性抑制剤
JPH07126618A (ja) * 1993-11-04 1995-05-16 Jumoku Chushutsu Seibun Riyou Gijutsu Kenkyu Kumiai 抗酸化剤
EP0824355A4 (en) * 1995-04-14 1998-12-30 Univ Southern California Mistletoe extract and method
US5565200A (en) * 1995-04-14 1996-10-15 University Of Southern California Pharmaceutical preparations derived from korean mistletoe
US6039950A (en) * 1995-04-14 2000-03-21 University Of Southern California Pharmaceutical grade saw palmetto
US5547674A (en) * 1995-04-14 1996-08-20 University Of Southern California Pharmaceutical preparations derived from European mistletoe

Also Published As

Publication number Publication date
CA2301860C (en) 2009-05-26
US6156291A (en) 2000-12-05
EP1006802A4 (en) 2004-01-14
CA2301860A1 (en) 1999-03-04
JP2001513533A (ja) 2001-09-04
CN1268027A (zh) 2000-09-27
JP2009292844A (ja) 2009-12-17
KR20010023208A (ko) 2001-03-26
WO1999009837A1 (en) 1999-03-04
EP1006802A1 (en) 2000-06-14
AU9029298A (en) 1999-03-16
JP5491114B2 (ja) 2014-05-14

Similar Documents

Publication Publication Date Title
JP5491114B2 (ja) 薬草抽出物の化学的および薬理学的標準化
Whitehouse et al. Reductions in [3H] nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: An autobiographic study
Kitagawa et al. Pharmacokinetic profiles of active ingredients and its metabolites derived from rikkunshito, a ghrelin enhancer, in healthy Japanese volunteers: a cross-over, randomized study
JP5906267B2 (ja) 学習・記憶障害および運動障害などを伴う中枢神経変性疾患を改善する乾燥植物組織および植物組織抽出物ならびにこれらを含有する医薬品および食品
Yuan et al. HS-GC-IMS-Based metabonomics study of Baihe Jizihuang Tang in a rat model of chronic unpredictable mild stress
Shan et al. Challenges in natural health product research: The importance of standardization
Chan et al. Quercetin Potentiates the NGF‐Induced Effects in Cultured PC 12 Cells: Identification by HerboChips Showing a Binding with NGF
CN107748212B (zh) 一种羊奶及其制品中检测药物的方法
Xu et al. Quality evaluation of traditional chinese medicine prescription in naolingsu capsule based on combinative method of fingerprint, quantitative determination, and chemometrics
Hu et al. Quantitative ternary network-oriented discovery of Q-markers from traditional Chinese medicine prescriptions: Bu-Zhong-Yi-Qi-Tang as a case study
Yang et al. Interventional effects of Pueraria oral liquid on T2DM rats and metabolomics analysis
CN113791152A (zh) 一种hplc法测定痫愈胶囊中多种有效成分含量的方法
CN115315266A (zh) 人参皂苷组合物
Rathod et al. Review on standardization an imp tool for herbal drug development
CN100364554C (zh) 灵芝咀嚼片的制备方法及产品
Wu et al. Novel neuroprotective tetramethylpyrazine analog T-006 promotes neurogenesis and neurological restoration in a rat model of stroke
CN102068656A (zh) 一种中药制剂羊痫疯癫丸的质量控制方法
Dimpfel et al. Zynamite®(Mangifera indica Leaf Extract) and Caffeine Act in a Synergistic Manner on Electrophysiological Parameters of Rat Central Nervous System
CN118121650A (zh) 一种中药提取物及其制备方法和入血成分的检测方法
Mădălina-Georgiana et al. Assessing β-sitosterol levels in dietary supplements for benign prostatic hyperplasia: implications for therapeutic efficacy
Xu et al. HPLC Fingerprint Analysis of Rana chensinensis Eggs from Different Habitats and Their Antitussive Effect
CN112924600A (zh) 一种治疗风湿痹阻所致关节肿痛制剂的指纹图谱建立方法
HK1027946A (en) Chemical and pharmacological standardization of herbal extracts
CN111474276B (zh) 一种健阳片制剂的质量控制方法
Kadam et al. Clinical Pharmacognosy

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050804

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080514

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20080514

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20080604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081015

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090114

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090918

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100427

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100520

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130528

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130528

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees